Related Experiment Videos
Targeted toxins
A E Frankel1, R J Kreitman, E A Sausville
1Wake Forest University School of Medicine, Winston-Salem, North Carolina 27157, USA. AFrankel@WFUBMC.edu
Abstract:
Targeted toxins, consisting of tumor-selective ligands coupled to polypeptide toxins, represent a new class of cancer therapeutics that kills malignant cells by inactivating cytosolic protein synthesis and inducing apoptosis. A number of these molecules have been produced under good manufacturing practice conditions and given systemically to patients with a variety of neoplasms. The promising results to date and the remaining pharmacological hurdles are discussed.
Insights
Targeted toxins, a novel cancer therapy, combine tumor-targeting molecules with toxins to kill cancer cells by halting protein synthesis and triggering apoptosis. Clinical studies show promise, but further research is needed to overcome pharmacological challenges.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- Targeted toxins represent a novel therapeutic strategy in cancer treatment.
- These agents comprise tumor-selective ligands conjugated to potent polypeptide toxins.
Purpose of the Study:
- To discuss the development and clinical application of targeted toxins.
- To review the mechanisms of action, promising results, and challenges associated with this therapeutic class.
Main Methods:
- Production of targeted toxins under good manufacturing practice (GMP) conditions.
- Systemic administration of these agents to patients with various neoplasms.
Main Results:
- Targeted toxins demonstrate efficacy by inactivating cytosolic protein synthesis.
- Induction of apoptosis in malignant cells is a key mechanism.
- Early clinical studies in patients with diverse cancers show promising outcomes.
Conclusions:
- Targeted toxins are a promising new class of cancer therapeutics.
- Further pharmacological research is essential to address existing hurdles for broader clinical application.